A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2
U
Utpal Dave, MD
Primary Investigator
Administratively Closed
18 years - 100 years
All
Phase
1/2
2 Locations
Brief description of study
A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: cancer,relapse peripheral T-cell lymphoma
-
Age: 18 years - 100 years
-
Gender: All
Updated on
03 Apr 2025.
Study ID: CTO-IPH4102-102, 11582, TX11414
